search
Back to results

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Primary Purpose

Relapsed or Refractory Hematological Malignancies

Status
Unknown status
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
CNCT19
Sponsored by
Shandong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Relapsed or Refractory Hematological Malignancies focused on measuring Relapsed, Refractory, Malignancy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Informed consent is signed by a subject or his lineal relation.
  2. Age 18 or older.
  3. Relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL)

    • Relapsed or refractory

      • Relapse within 12 months of first remission
      • Without remission after 2 cycles of induction chemotherapy regimen.
      • Without remission after more than 6 weeks of induction chemotherapy.
      • 2nd or greater Bone Marrow (BM) relapse
      • Any BM relapse after autologous/allogeneic stem cell transplantation (SCT)
    • documentation of cluster of differentiation 19 (CD19) tumor expression demonstrated in bone marrow or peripheral blood within 3 months of study entry.
    • Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 1generation and/or 2 generation of tyrosine kinase inhibitor therapy (TKI); no TKI salvage treatments if the patient has a BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) mutation.
    • Bone marrow with ≥ 5% lymphoblasts by morphologic assessment or minimal residual disease (MRD) positive at screening
  4. Relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with CD19-positive after two systemic lines of therapy

    • Chemotherapy-refractory disease, defined as one of more of the following:

      • No response to last line of therapy. i. Progressive disease (PD) as best response to most recent therapy regimen. ii. Stable disease (SD) as best response to most recent therapy with duration no longer than 6 month from last dose of therapy
      • Refractory post-autologous stem cell transplant (ASCT) or allogeneic stem cell transplantation (allo-HSCT).

        i. Disease progression or relapsed less than or equal to 12 months of ASCT /allo-HSCT (must have biopsy proven recurrence in relapsed individuals).

    ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy Any BM relapse after autologous/allogeneic stem cell transplantation (SCT).

    • Individuals must have received two systemic lines of therapy

      • anti-cluster of differentiation 20 (CD20) monoclonal antibody unless investigator determines that tumor is CD20-negative and
      • an anthracycline containing chemotherapy regimen
  5. Relapsed or refractory chronic lymphocytic leukemia (CLL) with CD19-positive Diagnosis of CLL that meets 2008 the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) diagnostic criteria, must have at least one of the following criteria.

    • Patients with Del(17p) / tumour suppressor p53 (TP53) mutation
    • CLL relapsed or refractory after 2 or more lines of therapy, Relapsed is defined as evidence of disease progression after a period of 6 months or more following an initial CR or PR.

    Refractory disease is defined as failure to achieve a response after 6 cycles of induction chemotherapy or having disease progression within 6 months of the last treatment.

  6. At least one measurable lesion, defined as at least 1 lymph node >1.5 cm in the longest diameter, per revised IWG Response Criteria.
  7. Eastern cooperative oncology group (ECOG) performance status of 0 to 2.
  8. Adequate organ function defined as:

    • Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤3 upper limit of normal (ULN)
    • Total bilirubin ≤ 2 ULN, except in individuals with Gilbert's syndrome; Note: Patients with Gilbert's syndrome that bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN will be eligible.
    • A serum creatinine≤ 1.5 ULN or Creatine removal rate ≥ 60mL/min(Cockcroft and Gault)
    • Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and oxygen saturation > 91% on room air.
    • International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (APTT) ≤ 1.5 ULN.
  9. Women of child-bearing potential and all male participants must use highly effective methods of contraception for a period of 1 year after the CNCT19 infusion.

Exclusion Criteria:

  1. Active central nervous system (CNS) involvement by malignancy.
  2. Patients with systemic vasculitis (such as Wegener granulomatosis, nodular polyarteritis, systemic lupus erythematosus) and active or uncontrolled autoimmune disease (such as autoimmune hemolytic anemia, etc.)
  3. Patients who are positive for any of HIV antibody, TP antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) antibody.
  4. During the first four weeks of screening, the patient underwent major surgery which was assessed by the investigator as unsuitable for enrollment;
  5. The patient's heart fits any of the following conditions:

    Left Ventricular Ejection Fraction (LVEF) ≤45%; III/IV congestive heart failure (NYHA); Severe arrhythmia (except for Atrial fibrillation, Paroxysmal supraventricular tachycardia); corrected QT interval (QTc)≥450ms (male)or QTc≥470ms (female)(QTc using Bazett's(QTcB)=QT/RR^0.5); Myocardial infarction or Coronary Artery Bypass Graft Surgery, heart stent surgery.

    Other heart diseases that have been judged by the investigator to be unsuitable for receiving cell therapy.

  6. Patients with a history of epilepsy or other active central nervous system diseases.
  7. Has had treat with live vaccine within 6 weeks prior to screening;
  8. Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.).
  9. Life expectancy < 12 weeks.
  10. Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.

Sites / Locations

  • Qilu Hospital of Shandong UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

A

Arm Description

Single dose of CNCT19

Outcomes

Primary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Overall remission rate (ORR)

Secondary Outcome Measures

Response at Day 28±3 days
Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) (partial remission,PR) at month 6 without SCT between CNCT19 infusion and Month 6 response assessment.
Percentage of patients who achieve CR or CRi (PR) with minimal residual disease negative bone marrow.
Relapse-free survival
Progression-free survival
Percentage of patients who achieve best overall response (BOR)
Duration of remission (DOR)
Overall survival
Percentage of patient who achieve CR or CRi (PR) and then proceed to stem cell transplantation(SCT) while in remission.
Proportion of patients with detectable replication competent lentivirus (RCL) by vesicular stomatitis virus, glycoprotein (VSV-G)

Full Information

First Posted
July 3, 2019
Last Updated
July 4, 2019
Sponsor
Shandong University
Collaborators
Juventas Cell Therapy Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04011293
Brief Title
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
Official Title
A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 2019 (Anticipated)
Primary Completion Date
July 2020 (Anticipated)
Study Completion Date
April 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shandong University
Collaborators
Juventas Cell Therapy Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.
Detailed Description
This is a single arm, open-label, single-center study to determine the safety and efficacy of CNCT19 in adult patients with r/r B cell Malignancies. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total duration of the study is 2 years from CNCT19 cell infusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsed or Refractory Hematological Malignancies
Keywords
Relapsed, Refractory, Malignancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
Single dose of CNCT19
Intervention Type
Biological
Intervention Name(s)
CNCT19
Intervention Description
0.5 to 4 x 10^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10^8 autologous CNCT19 transduced cells via intravenous infusion.
Primary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame
24 months
Title
Overall remission rate (ORR)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Response at Day 28±3 days
Time Frame
1 month
Title
Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) (partial remission,PR) at month 6 without SCT between CNCT19 infusion and Month 6 response assessment.
Time Frame
6 months
Title
Percentage of patients who achieve CR or CRi (PR) with minimal residual disease negative bone marrow.
Time Frame
6 months
Title
Relapse-free survival
Time Frame
24 months
Title
Progression-free survival
Time Frame
24 months
Title
Percentage of patients who achieve best overall response (BOR)
Time Frame
24 months
Title
Duration of remission (DOR)
Time Frame
24 months
Title
Overall survival
Time Frame
24 months
Title
Percentage of patient who achieve CR or CRi (PR) and then proceed to stem cell transplantation(SCT) while in remission.
Time Frame
24 months
Title
Proportion of patients with detectable replication competent lentivirus (RCL) by vesicular stomatitis virus, glycoprotein (VSV-G)
Time Frame
at Month 3 post treatment then Month 6 and Month12, yearly until year 15 if CD19 chimeric antigen receptor (CAR) transgene is still detected

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent is signed by a subject or his lineal relation. Age 18 or older. Relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL) Relapsed or refractory Relapse within 12 months of first remission Without remission after 2 cycles of induction chemotherapy regimen. Without remission after more than 6 weeks of induction chemotherapy. 2nd or greater Bone Marrow (BM) relapse Any BM relapse after autologous/allogeneic stem cell transplantation (SCT) documentation of cluster of differentiation 19 (CD19) tumor expression demonstrated in bone marrow or peripheral blood within 3 months of study entry. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 1generation and/or 2 generation of tyrosine kinase inhibitor therapy (TKI); no TKI salvage treatments if the patient has a BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) mutation. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment or minimal residual disease (MRD) positive at screening Relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with CD19-positive after two systemic lines of therapy Chemotherapy-refractory disease, defined as one of more of the following: No response to last line of therapy. i. Progressive disease (PD) as best response to most recent therapy regimen. ii. Stable disease (SD) as best response to most recent therapy with duration no longer than 6 month from last dose of therapy Refractory post-autologous stem cell transplant (ASCT) or allogeneic stem cell transplantation (allo-HSCT). i. Disease progression or relapsed less than or equal to 12 months of ASCT /allo-HSCT (must have biopsy proven recurrence in relapsed individuals). ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy Any BM relapse after autologous/allogeneic stem cell transplantation (SCT). Individuals must have received two systemic lines of therapy anti-cluster of differentiation 20 (CD20) monoclonal antibody unless investigator determines that tumor is CD20-negative and an anthracycline containing chemotherapy regimen Relapsed or refractory chronic lymphocytic leukemia (CLL) with CD19-positive Diagnosis of CLL that meets 2008 the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) diagnostic criteria, must have at least one of the following criteria. Patients with Del(17p) / tumour suppressor p53 (TP53) mutation CLL relapsed or refractory after 2 or more lines of therapy, Relapsed is defined as evidence of disease progression after a period of 6 months or more following an initial CR or PR. Refractory disease is defined as failure to achieve a response after 6 cycles of induction chemotherapy or having disease progression within 6 months of the last treatment. At least one measurable lesion, defined as at least 1 lymph node >1.5 cm in the longest diameter, per revised IWG Response Criteria. Eastern cooperative oncology group (ECOG) performance status of 0 to 2. Adequate organ function defined as: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤3 upper limit of normal (ULN) Total bilirubin ≤ 2 ULN, except in individuals with Gilbert's syndrome; Note: Patients with Gilbert's syndrome that bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN will be eligible. A serum creatinine≤ 1.5 ULN or Creatine removal rate ≥ 60mL/min(Cockcroft and Gault) Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and oxygen saturation > 91% on room air. International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (APTT) ≤ 1.5 ULN. Women of child-bearing potential and all male participants must use highly effective methods of contraception for a period of 1 year after the CNCT19 infusion. Exclusion Criteria: Active central nervous system (CNS) involvement by malignancy. Patients with systemic vasculitis (such as Wegener granulomatosis, nodular polyarteritis, systemic lupus erythematosus) and active or uncontrolled autoimmune disease (such as autoimmune hemolytic anemia, etc.) Patients who are positive for any of HIV antibody, TP antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) antibody. During the first four weeks of screening, the patient underwent major surgery which was assessed by the investigator as unsuitable for enrollment; The patient's heart fits any of the following conditions: Left Ventricular Ejection Fraction (LVEF) ≤45%; III/IV congestive heart failure (NYHA); Severe arrhythmia (except for Atrial fibrillation, Paroxysmal supraventricular tachycardia); corrected QT interval (QTc)≥450ms (male)or QTc≥470ms (female)(QTc using Bazett's(QTcB)=QT/RR^0.5); Myocardial infarction or Coronary Artery Bypass Graft Surgery, heart stent surgery. Other heart diseases that have been judged by the investigator to be unsuitable for receiving cell therapy. Patients with a history of epilepsy or other active central nervous system diseases. Has had treat with live vaccine within 6 weeks prior to screening; Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.). Life expectancy < 12 weeks. Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chuanli Zhao, Dr.
Phone
‭+86 185 6008 7009‬
Email
chuanlizhao@163.com
Facility Information:
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chuanli Zhao, Dr.
Phone
‭+86 185 6008 7009‬
Email
chuanlizhao@163.com
First Name & Middle Initial & Last Name & Degree
Chunyan Ji, Dr.

12. IPD Sharing Statement

Learn more about this trial

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

We'll reach out to this number within 24 hrs